Legacy Tech's AI Transformation
IBM's strong quarterly results, driven by its growing AI business, highlight a significant trend of legacy technology systems being revitalized by artificial intelligence. This shift creates a compelling investment case for companies specializing in enterprise-level AI integration, data management, and hybrid cloud solutions.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
Legacy technology companies are experiencing a renaissance through AI integration. IBM's recent strong quarterly results, driven by over $7.5 billion in AI business, demonstrate how established enterprises can successfully pivot to high-growth AI areas. This creates opportunities for companies that facilitate enterprise-level AI adoption across data management, hybrid cloud infrastructure, and consulting services.
What You Need to Know
This group focuses on the enterprise AI transformation cycle, where large organizations are upgrading their existing systems with artificial intelligence. These stocks represent companies positioned across the value chain - from data platforms to cloud infrastructure to AI-powered services. The theme captures businesses that enable rather than compete with the AI transformation happening in corporate America.
Why These Stocks
These companies were handpicked as critical enablers of the enterprise AI shift. Each business provides specialized solutions that large organizations need when integrating AI into their existing systems. Professional analysts selected these stocks based on their strategic positioning to benefit from the widespread technological upgrade cycle happening across industries.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+49.93%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 49.93% over the next year.
Stocks Rated Buy by Analysts
12 of 16 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Enterprise AI Gold Rush
IBM's $7.5 billion AI business proves that legacy tech transformation is real and profitable. Companies enabling this shift are positioned to capture massive enterprise spending on AI integration.
Transformation Cycle Just Starting
Most large organizations are still in early stages of AI adoption. This creates a multi-year opportunity for companies providing the infrastructure and services needed for enterprise AI transformation.
Hidden Value in Enablers
While everyone focuses on AI creators, the real winners might be the companies that help existing businesses integrate AI into their operations. These picks target that overlooked opportunity.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.